LENZ Therapeutics (LENZ) Insider Mccollum Buys 22,100 Shares

Insider Buying and Selling at LENZ Therapeutics, Inc.

On June 15, 2026, James Mccollum bought 22,100 shares of LENZ (NasdaqGS: LENZ). This purchase adds to a wave of insider buying on the same day, as multiple insiders also acquired the same amount of shares.

A Trend of Insider Buying

Mccollum's purchase is part of a larger trend, with insiders like L.P. Ra Capital Management, Jeffrey George, Kimberlee Drapkin, Shelley Thunen, Frederic Guerard, and Zachary Scheiner all buying 22,100 shares each on June 15. This collective action could signal strong confidence in the company's future prospects among its executives.

How LENZ Stock Has Traded

LENZ stock is currently trading at $6.77, which is close to its 52-week low of $4.00. The stock has seen significant fluctuations, hitting a high of $50.40 in the past year. The insider purchases come at a time when the stock is below its 200-day moving average of $10.27, suggesting that insiders might see value at this lower price point.

Analysts Set New Price Targets

Analysts have varied opinions on LENZ. On August 12, 2026, Piper Sandler maintained a Neutral rating with a price target of $7.00, down from a previous target of $12.00. Meanwhile, on July 7, 2026, HC Wainwright & Co. reiterated a Buy rating with a target of $38.00. The mixed ratings reflect differing views on the company's growth potential as it develops its product pipeline.

What LENZ Does

LENZ Therapeutics, Inc. is focused on creating therapies to improve vision. Its key products include VIZZ and LNZ101, aimed at treating presbyopia in adults. The company's recent insider buying may indicate a belief in its future success as it advances its offerings.

What’s Next for LENZ

Investors should keep an eye on the upcoming earnings report scheduled for November 4, 2026. The recent insider activity, combined with analyst ratings, suggests a period of scrutiny for the company as it continues to navigate its development and market position.